| scholarly article | Q13442814 |
| P50 | author | Richard W Groen | Q57549123 |
| Gang G Wang | Q80521785 | ||
| Jian Jin | Q87659760 | ||
| Alan J Tackett | Q89571849 | ||
| Yi-Hsuan Tsai | Q91164889 | ||
| Jeong Hyun Ahn | Q92429860 | ||
| Aaron J Storey | Q92429865 | ||
| P2093 | author name string | Benjamin A Garcia | |
| Ping Wang | |||
| Deyou Zheng | |||
| Samuel G Mackintosh | |||
| Ricky D Edmondson | |||
| Brian Koss | |||
| Ling Cai | |||
| Natarajan V Bhanu | |||
| Hequn Liu | |||
| Anton C Martens | |||
| Anqi Ma | |||
| David F Allison | |||
| Zhihong Ren | |||
| P2860 | cites work | MTF2 recruits Polycomb Repressive Complex 2 by helical-shape-selective DNA binding | Q58374489 |
| Capturing the Onset of PRC2-Mediated Repressive Domain Formation | Q61031838 | ||
| PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism | Q64057193 | ||
| H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis | Q64077203 | ||
| Deciphering the chronology of copy number alterations in Multiple Myeloma | Q64112513 | ||
| A687V EZH2 is a gain-of-function mutation found in lymphoma patients | Q84689750 | ||
| Understanding histone H3 lysine 36 methylation and its deregulation in disease | Q92420533 | ||
| Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation | Q92688588 | ||
| lncRNA-Induced Spread of Polycomb Controlled by Genome Architecture, RNA Abundance, and CpG Island DNA | Q93137470 | ||
| JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells | Q24295145 | ||
| Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity | Q24301878 | ||
| Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation | Q24304060 | ||
| An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting | Q24307370 | ||
| Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers | Q24605342 | ||
| Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis | Q24607308 | ||
| Initial genome sequencing and analysis of multiple myeloma | Q24629117 | ||
| Role of hPHF1 in H3K27 methylation and Hox gene silencing | Q24658072 | ||
| Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2 | Q27702306 | ||
| Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin | Q27851546 | ||
| Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes | Q27851571 | ||
| Role of histone H3 lysine 27 methylation in Polycomb-group silencing | Q28131795 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells | Q28585926 | ||
| Polycomb-like 3 promotes polycomb repressive complex 2 binding to CpG islands and embryonic stem cell self-renewal | Q28587391 | ||
| Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) | Q29147438 | ||
| The Polycomb complex PRC2 and its mark in life | Q29547358 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| Jarid2 and PRC2, partners in regulating gene expression | Q33631152 | ||
| Indicators of responsiveness to immune checkpoint inhibitors | Q33678048 | ||
| The role of STATs in transcriptional control and their impact on cellular function | Q33941346 | ||
| Druggability of methyl-lysine binding sites | Q34093054 | ||
| Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation | Q34133622 | ||
| Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma | Q34326046 | ||
| An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1 | Q34341058 | ||
| Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas | Q34397318 | ||
| Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma | Q34451553 | ||
| Genome-wide association study identifies multiple susceptibility loci for multiple myeloma | Q34677689 | ||
| Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia | Q34876825 | ||
| Polycomb genes, miRNA, and their deregulation in B-cell malignancies | Q35103527 | ||
| Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia | Q35742745 | ||
| Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3 | Q36187444 | ||
| Targeting EZH2 and PRC2 dependence as novel anticancer therapy | Q36445523 | ||
| Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma | Q36745120 | ||
| Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. | Q36916348 | ||
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation | Q36926825 | ||
| Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development | Q37095702 | ||
| Heterogeneity of genomic evolution and mutational profiles in multiple myeloma | Q37528285 | ||
| Tudor: a versatile family of histone methylation 'readers'. | Q38137526 | ||
| Transcriptional regulation by Polycomb group proteins | Q38149730 | ||
| Role of PRC2-associated factors in stem cells and disease | Q38255769 | ||
| Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma | Q38259785 | ||
| A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. | Q38333859 | ||
| Targeting Polycomb systems to regulate gene expression: modifications to a complex story | Q38595464 | ||
| EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas | Q38713519 | ||
| EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes | Q38817953 | ||
| PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. | Q38954754 | ||
| Maintaining cell identity: PRC2-mediated regulation of transcription and cancer | Q38961785 | ||
| Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma | Q39261435 | ||
| A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. | Q39980314 | ||
| Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. | Q40011376 | ||
| The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. | Q41757434 | ||
| A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia | Q42053261 | ||
| Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition | Q42776492 | ||
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy | Q43024864 | ||
| Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma | Q43077293 | ||
| Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors | Q44911894 | ||
| Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib | Q44937333 | ||
| UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition | Q47098704 | ||
| DNA binding by PHF1 prolongs PRC2 residence time on chromatin and thereby promotes H3K27 methylation. | Q47421523 | ||
| Polycomb-like proteins link the PRC2 complex to CpG islands. | Q47859713 | ||
| Signalling crosstalk during early tumorigenesis in the absence of Polycomb silencing | Q48193312 | ||
| The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells. | Q52335124 | ||
| Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding. | Q52369369 | ||
| The multiple myelomas - current concepts in cytogenetic classification and therapy. | Q52717229 | ||
| ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer | Q56886543 | ||
| PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs | Q57035464 | ||
| P433 | issue | 14 | |
| P304 | page(s) | 1176-1189 | |
| P577 | publication date | 2019-08-05 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation | |
| P478 | volume | 134 |
| Q101166870 | BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis |
| Q96576366 | Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns |
| Q97069663 | Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion |
| Q89723295 | Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease |
| Q90379556 | PHD Finger Protein 19 Enhances the Resistance of Ovarian Cancer Cells to Compound Fuling Granule by Protecting Cell Growth, Invasion, Migration, and Stemness |
| Q91641243 | hPCL3S promotes proliferation and migration of androgen-independent prostate cancer cells |
Search more.